Current state of quality of life and patient-reported outcomes research by Bottomley, A et al.
European Journal of Cancer 121 (2019) 55e63Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer .comCurrent PerspectiveCurrent state of quality of life and patient-reported
outcomes researchAndrew Bottomley a,*, Jaap C. Reijneveld b, Michael Koller c,
Henning Flechtner d, Krzysztof A. Tomaszewski e,f, Eva Greimel g on
behalf of the 5th EORTC Quality of Life in Cancer Clinical Trials
Conference Faculty1a Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
b Department of Neurology and Brain Tumor Center, Amsterdam University Medical Center, Amsterdam, The Netherlands
c Center for Clinical Studies, University Hospital Regensburg, Germany
d University Clinic for Child and Adolescent Psychiatry, Otto-von-Guericke-University, Magdeburg, Germany
e Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
f Scanmed St. Raphael Hospital, Cracow, Poland
g Department of Gynecology, Medical University Hospital, Graz, AustriaReceived 6 August 2019; accepted 8 August 2019KEYWORDS
Quality of life;
Patient-reported
outcomes;
Symptom assessments;
Cancer treatment;
Cancer patients;
Cancer survivorship* Corresponding author: Quality of Lif
Brussels, 1200, Belgium.
E-mail address: andrew.bottomley@
1 See Addendum.
https://doi.org/10.1016/j.ejca.2019.08.016
0959-8049/ª 2019 The Author(s). Pu
creativecommons.org/licenses/by-nc-nd/Abstract The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the
current state of quality of life and other patient-reported outcomes (PROs) research from the
perspectives of researchers, regulators, industry representatives, patients and patient
advocates and health care professionals. A major theme was the assessment of the burden
of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO
assessments in clinical trials, patients’ experiences in cancer clinical trials, innovative methods
and standardisation in cancer research, innovative methods across the disease sites or
populations and cancer survivorship. Conferees demonstrated that PROs are becoming more
accepted and major efforts are ongoing internationally to standardise PROs measurement,
analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to
ensure that the right questions are asked and the right answers are communicated. Improved
technology and increased flexibility of measurement instruments are making PROs data moree Department, European Organisation for Research and Treatment of Cancer, 83/11 Avenue E. Mounier,
eortc.be (A. Bottomley).
blished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
A. Bottomley et al. / European Journal of Cancer 121 (2019) 55e6356robust. Patients are being encouraged to be patient partners. International collaborations are
essential, because this work cannot be accomplished on a national level.
ª 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The 5th EORTC Quality of Life in Cancer Clinical
Trials Conference presented the current state of quality
of life (QOL) and other patient-reported outcomes
(PROs) research from the perspectives of QOL re-
searchers, regulators, industry representatives, patients
and patient advocates and health care professionals.
PROs are any clinical outcome reported directly by the
patient and captured either through self-reporting or
interview (as long as the interviewer directly records the
patient’s responses). Health-related QOL is a multidi-
mensional concept referring to the patient’s subjective
perception of the effect of their disease and treatment on
physical, psychological and social aspects of daily life.
PROs are particularly important today, because a clin-
ical response to treatment might well be observed, but at
the expense of worsening the patient’s condition.
Indeed, drug efficacy in cancer clinical trials is assessed
by end-points such as overall survival or tumour
growth, but cancer treatments are often accompanied
with side-effects that can adversely affect QOL. Symp-
tom assessment can offer greater precision in describing
the patient’s experience, and these can strengthen the
response to change in intervention trials, especially when
they focus on a key treatment benefit or expected
toxicity. The challenge, although, is being able to sepa-
rate disease-related symptoms from treatment toxicity
[1].
Information concerning the trajectory of symptoms
can be obtained by collecting PROs data in an organ-
ised, longitudinal manner. In Edmonton, Canada, a
retrospective observational study collected the data of
391,305 patients diagnosed with cancer between
January 2007 and December 2014 with a recorded
3,277,585 symptom assessments. Considering the
assessment of pain, e.g. the study found that in most
cancer types, the proportion of patients with pain is
fairly stable over the disease course, the trajectory de-
pends on the type of cancer, and pain is higher in lung
cancer and lower in gastrointestinal cancers [2]. How-
ever, for head and neck cancers, the worst pain occurs
after treatment. Such information has important im-
plications for patients, and this study shows that pa-
tients, together with their health care provider, should
prepare a detailed treatment plan on how to address
post-treatment pain.2. Regulatory challenges in using PROs
Key drivers affect the regulatory environment: new and
emerging science, medicines and technologies; public
demand for greater transparency and openness; calls for
a patient-centred approach and involvement. Regulators
have to balance the benefits and risks of drug products.
As for risks, clinical trial adverse events will capture
disease-related symptoms and treatment-related symp-
toms together, which can be difficult to differentiate
from each other. Also, safety is not the same thing as
tolerability which has a component of patients’ decision
to adhere to a therapy that can be affected by symp-
tomatic adverse events. It is very difficult to label how
patients feel and function on a treatment, and these
comprise underlying reasons for regulatory interest in
PROs, and both the United States of America (USA)
Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA) have published guid-
ance on PROs [3,4]. Differences among FDA, EMA and
Health Canada in the way PROs are handled and
interpreted can limit the capacity of external stake-
holders to optimise clinical trial design and PROs data
collection to meet regulatory decision-making re-
quirements [5]. This makes continued international
collaboration among regulators and payer groups using
these data important.
In practice, obtaining scientific advice from regula-
tors helps to ensure that developers perform the
appropriate tests and studies. A recent study of 96 trials
from 2007 to 2017 for cancer products concluded that
implementation of procedures was needed to help
improve PROs completion rates and reduce missing
data [6]. To help this forward, both the EMA and FDA
have established programmes to provide parallel scien-
tific advice to sponsors which focus on sharing infor-
mation and perspectives, achieving harmonisation and
increasing convergence.
PROs provide a patient-focused assessment of the
impact of a treatment on the patients’ symptoms and
functional ability, and as such, PROs fit well within
personalised medicine. Challenges in using patient-re-
ported outcome measures (PROMs) include the
increasing molecular sub-classification of disease leading
to insufficient numbers of similar patients to reach sta-
tistical power in clinical trials. Data to support regula-
tory decision-making may rely on extrapolation of the
data on similar molecular tumour types at different
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are more susceptible to the effects of variability, and
missing data are more likely to impact the study con-
clusions. Smaller pre-market exposure equates with
increased importance of, and emphasis on, post-market
monitoring and data collection. Consequently, the use
of real world evidence (RWE) is gaining attention as a
way to support regulatory decision making [7].
Study design is important, and when deployed PROs
end-points should be stated as specific clinical trial ob-
jectives in the study protocol and statistical analysis
plan. The extent to which the inclusion of PROMs can
provide added value to the clinical trial should be
defined. Here, it should be noted that the most appro-
priate and valid PROMs have involved patients in their
development. PROMs are best considered early in the
development programme, and patients should be
involved early in the study design process. PROMs
should be administered to study subjects at time points
when there is a clear rationale for their use. Excessively
high numbers of questions can constitute an undue
burden to the patient, and efforts to select only those
questions that are relevant to the trial context may
decrease high drop-out rates and missing data. When
reporting results, a balanced view of PROs-QOL should
be presented, and any disconnect between QOL results
and other safety and efficacy end-points should be
addressed.
3. Sponsor’s perspective on QOL
It could be said that in the past, clinical trial end-points
were not defined to compare QOL between treatments,
did not start with a clear hypothesis to explore the dif-
ferences in QOL, nor measured aspects of disease and
treatment most relevant to patients. Today, however,
there is greater alignment on core concepts of interest
from the perspectives of regulators, patients and health
care providers, e.g. disease symptoms, physical func-
tioning, instrumental activities of daily living, treatment
burden, as well as alignment on well-defined tools and
end-points.
Looking forward, there is still room for clearer end-
point definitions, better alignment between sponsors and
regulators balancing rigor and feasibility, better up-
front communication between regulators and sponsors,
clearer alignment between payers and regulators on re-
quirements for clinical evidence, clearer expectations of
filing requests at preephase III meetings, and clearer
alignment between payers and regulators on re-
quirements for clinical evidence. Comparative tolera-
bility of a medical product should include direct
measurement from patients on how they are feeling and
functioning while on treatment. In addition, the future
will see an increase in the use of new study designs, a
movement towards decentralised, yet still international,clinical trials and systematic patient input into trial
design and feasibility.
An increase in novel treatments, such as cell and gene
therapies, where limited empirical evidence is available
at approval, points towards an increased importance for
RWE. In rare cancers, where patients are scarce, PROs
as part of routine care can provide valuable information
on the patient’s experience.
4. QOL assessment in clinical trials
PROs data relating to a new treatment are an important
complement to the clinical evidence in demonstrating
the value of a treatment; however, the lack of stand-
ardisation can lead to variation in result analysis and
end in potential differences in data interpretation.
Carefully validated static questionnaires such as the
EORTC QLQ-C30 and modules have become the norm,
and this is good news. However, sometimes it is desir-
able to measure the core domains with greater flexibility
to achieve greater precision (e.g. primary outcome),
allow patients to answer fewer questions or capture
higher levels of functioning or more severe symptoms
(expand measurement range). With this in mind, the
EORTC Quality of Life Group (QLG) is introducing a
new flexible strategy for QOL assessment that builds on
their traditional approach. To optimise measurement
precision and flexibility, a computerised adaptive test
(CAT) version of the EORTC QLQ-C30 has been
developed. With CAT, the selection of items is tailored
to the individual based on responses to previous items
[8]. The EORTC CAT enables increased precision and
requires a smaller sample, provides reduced response
burden, reduced floor and ceiling effects, offers a ques-
tionnaire length selected for each study or person indi-
vidually with immediate calculation of scores and
remains compatible with the QLQ-C30.
Multiple hurdles must be overcome before we can
effectively measure, appropriately specify, properly
analyse, clearly report and successfully apply PROs
findings from clinical trials in clinical practice. In this
light, the Patient-Reported Outcomes Tools: Engaging
Users and Stakeholders consortium has set out to ensure
that patients, clinicians and other decision-makers have
PROs data from clinical trials to make the best decisions
they can about treatment options, and they are doing
this by partnering with key stakeholder groups to
disseminate and implement tools that have been devel-
oped to optimise the use of PROs in clinical trials
[9e15].
The relationship between PROs and survival is well-
established, although the mechanisms that explain why
PROs predict survival do need to be identified [16,17].
Still, there is considerable potential to use these data in
cancer care. PROs could be used as eligibility criteria or
stratification factor in cancer clinical trials, opening the
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care, or to be used to provide interventions to improve
PROs and survival time.
Modern cancer therapy has been advanced through a
better understanding of genetics and the underlying
molecular biology. Trials of diagnostics, surgical and
radiotherapy techniques and targeted systemic therapies
demonstrate that more patients are being cured or are
living with their cancers for longer periods of time [18].
Even so, questions remain. Is lengthier survival worth
treatment side-effects, and what survival benefit is
needed to trade off disadvantages and harms? Certainly,
current research suggests a flawed logic behind the idea
that patients will accept high toxicity for minimal ben-
efits. Indeed, if there is no clear survival benefit between
treatments, then differences in QOL between those
treatments are crucial and may influence patient choices.
However, is there sufficient QOL data to inform patient
decision-making [19]?
In response to these questions, Patient-Reported
Outcomes in cancer, impact of Age and Carer/role de-
mands associated with Treatment has developed and
validated a Patient Roles and Responsibilities Scale to
enable a broader evaluation of the impact of cancer and
cancer treatment and measuring ‘real world’ roles and
responsibilities such as caring for others and financial
and employment responsibilities [20]. From the patients’
perspective, whether something is worthwhile is an in-
dividual thing. It is important to know if treatment will
allow them to carry on those daily activities that give
their lives meaning.
Patient advocates see an opportunity for PROs to
move centre stage in research as a means towards
developing and understanding pathways of care. PROs
tools, methods and support need development. The
rounded holistic view provided by longitudinal studies
is highly desired. Patient advocates point out that
research participation is linked to high numbers of
satisfied patients, and research delivery is linked to
improved outcomes (both in institutions and in patient
populations).5. Innovative methods and standardisation in cancer
research
Guidelines are recommendations intended to assist
providers and recipients of health care and other
stakeholders to make informed decisions, are condi-
tional, and generally gain support with implementation
[21]. Recommendations can be confusing in practice, so
GRADE (Grading of Recommendations Assessment,
Development and Evaluation) has developed a unify-
ing, transparent, system for grading the certainty of
evidence and making decisions [22]. The practical use of
this tool can be seen, e.g., by applying it to situations in
conjunction with the European Breast Guidelines. Asan example, mammography screening programmes are
organised for women more than 50 years old, but
should you attend if you are 45e49 years old?
GRADE, an interactive decision aid, considers the
problem, desirable as well as undesirable effects, cer-
tainty of evidence, value, balance of effects, resources,
the certainty of evidence of required resources, cost
effectiveness, equity, acceptability, and feasibility to
reach a suggestion for intervention. In this example,
GRADE suggested the intervention: ‘For asymptom-
atic women aged 45e49 years with an average risk of
breast cancer, the European Commission Initiative on
Breast Cancer Guideline Development Group recom-
mends mammography screening over no screening, in
the context of an organised screening programme
(conditional recommendation, moderate certainty in
the evidence)’.
Clinical trial protocols enable research teams to
deliver a high-quality study. As such, protocols should
provide sufficient detail to enable funders, reviewers and
institutional review boards to appraise scientific, meth-
odological and ethical rigor. These are, therefore, a
major determinant of the quality of PROs data and the
subsequent evidence. An international, consensus-based,
PRO-specific protocol guidance was developed, an
official Standard Protocol Items: Recommendations for
Interventional Trials-Patient reported outcomes
(SPIRIT-PROs) extension, to ensure that PROs data
will be of high-quality and thus able to better inform
patient care [10].
The EORTC Quality of Life core questionnaire, the
QLQ-C30, maintains a sufficient degree of general-
isability to allow for cross-cultural comparison along
with a level of specificity adequate for addressing research
questions of particular relevance in a given cancer clinical
trial. It uses a modular approach applicable to all people
with cancer. The current EORTC portfolio includes
QLQ-C30 questionnaires available in over 110 languages,
the QLQ-C15-PAL short version for palliative care, the
QLQ-F17 short version with only functional scales and
stand-alone questionnaires on, e.g. information and
satisfaction with care. Apart from that, there are a total
of 27 fully validated disease-specific modules that can be
used in conjunction with the QLQ-C30 and are available
for academic and commercial use.
If a researcher would like to assess QOL in a clinical
trial, but there is no suitable EORTC instrument, then
the EORTC item library can be consulted. EORTC
QLG strategy supports the combining of static and
flexible measures. Currently, the library has over 900
items (i.e. questions) from over 60 questionnaires, up to
110 language versions per item, and researchers are able
to create and download item lists. Using item lists can
reduce patient burden by minimising the number of
measures required as well as provide increased flexibility
and efficiency that can be more tailored to the needs of
specific treatments and populations. However, the item
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compare across trials.
The USA National Cancer Institute (NCI) developed
the Patient-Reported Outcomes Version of the Common
Terminology Criteria for Adverse Events (PROs-
CTCAE) to integrate the patient perspective into
adverse event reporting [23]. The PROs-CTCAE item
library contains 124 patient-reported items representing
78 symptomatic adverse events (e.g. dysphagia, nausea,
sensory neuropathy). Items assess frequency, severity,
interference with daily activities, presence and amount.
Covered adverse events are drawn from the NCI’s
CTCAE.
Setting International Standards for the Analysis of
Quality of Life (SISAQOL) led by the EORTC [24], is
an international multi-stakeholder consortium with
shared interest in improving the standards for the sta-
tistical analysis of PROs. Its current focus is on rando-
mised clinical trials (RCTs) in oncology. A common
PROs objective is, e.g. will treatment A improve phys-
ical functioning relative to treatment B. So, which sta-
tistical measure is appropriate to test this? Each
statistical method focuses on a different aspect of the
data and responds to a different research objective, and
SISAQOL has developed a taxonomy of research ob-
jectives that can help inform the statistical method to be
used. SISAQOL’s ultimate goal is to draw robust and
clear conclusions based on PROs assessments so that
treatments can deliver better patient outcomes. That
said, within a treatment arm for a given PROs objective,
you might not feel better with the treatment, but you
might not feel as bad as you would with the other.
QOL is increasingly assessed as an important end
point in cancer clinical trials, and there is a simulta-
neously growing interest to improve the interpretation
of QOL data. Interpreting QOL scores merely via sta-
tistical significance might be misleading, because small
differences in mean scores can be statistically significant,
even when clinical relevance is absent. Therefore, the
notion of minimally important difference (MID) aids in
interpreting differences and changes in QOL scores as
clinically meaningful. A recent EORTC study, however,
found that a global rule for MIDs applicable to all
settings is unlikely [25]. MIDs vary by EORTC QLQ-
C30 scale, direction of change and disease setting, and
there is need to update and diversify current MID
standards.
Lessons can be learned by looking back at analyses of
QOL in clinical trials. EORTC trial 18071, e.g. is over-
powered for QOL differences, and because of the multi-
ple tests conducted, differences would be rated according
to their magnitude rather than statistical significance [26].
The MIDZ 10 points, thus differences of <10 points are
not considered clinically relevant. So, expecting QOL
improvement needs more than efficacy improvement, and
this is difficult to achieve. Patients not responding well
tend to drop out, and consequently there is a selectioneffect. In EORTC trial 62072, longer progression-free
survival led to longer pazopanib administration and,
therefore, QOL data were collected for a longer time
period. QOL assessment is limited until progression, so
the question of the added value of delayed progression
arises [27]. Here, post-progression QOL data collection is
required. Blinding has an impact on QOL: the expecta-
tions are unchanged, uncertainty is added and adverse
events are seen as positive (as patients then presume that
they are in the experimental arm). Finally, it can be
argued that the general QOL scale is insensitive in that
the overall QOL is greater than the sum of symptoms and
is subject to coping mechanisms, response shifts, remedial
therapies, etc.
A systematic review of 46 RCTs of biomedical in-
terventions and 20 RCTs of psychosocial interventions
was conducted in 2003 to determine the contribution of
QOL to decision-making [28]. In adjuvant therapy of
breast cancer, QOL provided additional information for
clinical decision-making beyond that of traditional
medical outcomes to primary local management, but did
not contribute to adjuvant chemotherapy or treatment
of metastatic disease, and the authors of the study rec-
ommended targeting specific symptoms and psycholog-
ical outcomes. A more recent analysis conducted
between 2001 and 2017 found that among 66 studies
reporting PROs results from RCTs of adult patients
with advanced breast cancer receiving anti-cancer
treatments, only eight (12%) studies reported a specific
PROs research hypothesis [29].
Finally, on another note, wearable electronic devices
offer the possibility of obtaining ePROs and the promise
of less missing data, more facile data monitoring,
circumvention of transmission and calculation errors as
well as the realisation of capturing QOL data in real
time. From a cost perspective, patients could essentially
bring their own device and, thereby, reduce cost. Efforts
are ongoing concerning validation of such devices.6. Innovative methods across disease sites and populations
There are a number of unique challenges faced when
QOL researchers develop QOL measurement in-
struments. For one, validated questionnaires need to be
translated into the local language to be used by patients
in a given country. To accomplish this, the EORTC first
assesses the translatability of a questionnaire. This is
followed by forward translations, reconciliation, back-
ward translations, review, proofreading, pilot-testing on
patients, discussion of the results and finalisation of the
project. This procedure is followed during development
of new instruments as well as after validation, when
questionnaires are requested by external users.
Measuring sexual health (SH) in the oncology setting
is another challenge, because communication about SH
lacks a proactive approach by most health care
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care providers to discuss sexual issues, but it often re-
mains an unmet need during the course of treatment.
The EORTC SHQ-22 is a cross-cultural validated
measure applicable in multiple countries and national-
ities, which can be used to assess SH of cancer patients
in clinical trials as well as in clinical practice. It is short,
easy to understand and well accepted by patients, and
the measures may facilitate physician–patient commu-
nication and help to identify SH problems throughout
the course of treatment [30]. Neurological tumours
present another sort of challenge. There is an increasing
number of clinical trials and studies in glioma patients
that include QOL measures, but compliance with QOL
is often limited. This hampers interpretation of the re-
sults and leaves clinically relevant questions unan-
swered. COmbining clinical trial DAtabases in GLIOma
patients and RANO-PRO (Response Assessment in
Neuro-OncologyePRO) are two projects which have
been formed to address this need [31,32]. RANO-PRO is
a broad initiative which also includes radiological and
other outcome measures. Finally, the experiences of
adolescents and young adults (AYAs) with cancer are
unique: the types of cancer, the way it changes their
body, plans and life are different than for adults [33].
For instance, compared with their peers, children or
adults with cancer, AYAs are at increased risk of poorer
psychological functioning, less likely to comply with
treatment, more likely to engage in risk taking
behaviour and place a higher importance on their peer
relationships. Consequently, their needs and experiences
might not be fully captured by existing instruments [34].7. Cancer survivorship
In 2016, there were an estimated 15.5 million cancer
survivors living in the USA, and 62% were 65 years or
older. The population of cancer survivors is expanding,
there is a need to coordinate post-treatment care and the
increased comorbidity experienced by these survivors
from cancer treatments. Aging increases the risk of
chronic diseases such as heart disease, cancer, chronic
lower respiratory diseases, stroke, diabetes,
dementia and kidney disease, and the late effects of
cancer treatment may overlap with conditions associ-
ated with aging [35].
Given the increasing number of cancer survivors,
cancer clinical trials are now being designed to include
long-term follow-up to assess survival, late effects and
QOL. Long-term PROs follow-up was not always a part
of phase III RCTs once the primary end point was
reached, and this resulted in challenges from institu-
tional review boards when trying to approach these
patients later on. Alongside this reality, there is a need
to develop PROMs that capture the full range of issues
relevant to disease-free cancer survivors. The EORTCQOL cancer survivorship questionnaire is being devel-
oped to, first, capture the full range of physical,
mental and social QOL issues relevant to disease-free
cancer survivors and, second, at what point following
the completion of treatment should the questionnaire be
used [36]?
In a first of its kind effort to identify the research
priorities of cancer patients and survivors, National
Cancer Research Institute (NCRI) partnered with the
James Lind Alliance in a United Kingdomewide survey
and gathered more than 3500 responses from patients,
caregivers and health and social care professionals. The
Top 10 Living with and Beyond Cancer Research Pri-
orities were announced at the 2018 NCRI Cancer con-
ference [37]:
1. What are the best models for delivering long-term cancer
care including screening, diagnosing and managing long-
term side-effects and late-effects of cancer and its
treatment (e.g. primary and secondary care, voluntary
organisations, self-management, carer involvement, use
of digital technology, etc)?
2. How can patients and carers be appropriately informed
of cancer diagnosis, treatment, prognosis, long-term
side-effects and late effects of treatments, and how
does this affect their treatment choices?
3. How can care be better coordinated for people living
with and beyond cancer who have complex needs (with
more than one health problem or receiving care from
more than one specialty)?
4. What causes fatigue in people living with and beyond
cancer and what are the best ways to manage it?
5. What are the short-term and long-term psychological
impacts of cancer and its treatment and what are the
most effective ways of supporting the psychological
wellbeing of all people living with and beyond cancer,
their caregivers and families?
6. How can the short-term, long-term and late effects of
cancer treatments be (a) prevented, and/or (b) best
treated/managed?
7. What are the biological bases of side-effects of cancer
treatment and how can a better understanding lead to
improved ways to manage side-effects?
8. What are the best ways to manage persistent pain caused
by cancer or cancer treatments?
9. What specific lifestyle changes (e.g. diet, exercise and
stress reduction) help with recovery from treatment,
restore health and improve QOL?
10. How can we predict which people living with and
beyond cancer will experience long-term side-effects
(side-effects which last for years after treatment) and
which people will experience late effects (side-effects
which do not appear until years after treatment)?8. Conclusions
The 5th EORTC Quality of Life in Cancer Clinical
Trials Conference brought together researchers, regula-
tors, industry representatives, patients and patient
A. Bottomley et al. / European Journal of Cancer 121 (2019) 55e63 61advocates as well as health care professionals to discuss
the current state of PROs research. PROs are becoming
increasingly accepted by all stakeholders, and major
efforts are ongoing globally to make standards for
PROs assessment, analysis and reporting in cancer
clinical trials. A combination of improved technology
and more flexible instruments allows collection of more
robust PROs data. Regulators have joined in this effort
and are keen to collaborate with all stakeholders to
ensure that researchers ask the right questions and
communicate the right answers. Patients, too, are
encouraged to be patient partners. Finally, although
there is a place for national studies, international col-
laborations are essential and can provide a greater
impact.
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